Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis (NASDAQ:OCS) disclosed a notification under managers' transactions relating to the vesting and settlement of RSUs previously granted to director Arshad Khanani.

Rhea-AI Summary

Oculis (NASDAQ:OCS) disclosed a notification under managers' transactions relating to the vesting and settlement of RSUs previously granted to director Arshad Khanani. The notification references an RSU vest on 25 February 2026 and was published on 27 February 2026.

Argus Mar 2 session

-2.72% close to close Open Argus

Details

News Market Reaction – OCS

In the Mar 2 session, OCS declined 2.72%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement describes the vesting and settlement of RSUs previously granted to a company direc...

Analysis

This announcement describes the vesting and settlement of RSUs previously granted to a company director, continuing Oculis’s pattern of routine PDMR and compensation-related disclosures. It does not introduce new clinical or financial guidance. In context, the company recently advanced Privosegtor with Breakthrough Therapy Designation and funded development through equity offerings, and it maintains an F-3 registering up to 494,259 warrant shares with potential cash proceeds of $6.88M. Investors may watch for upcoming Phase 3 readouts and further regulatory updates as the key fundamental drivers.

Key Figures

Registered resale shares: 494,259 shares Currently exercisable warrant: 59,310 shares Exercise price tranche 1: $12.17 +5 more

Registered resale shares

494,259 shares

Form F-3 warrant share resale registration

Currently exercisable warrant

59,310 shares

Portion of warrant presently exercisable

Exercise price tranche 1

$12.17

Exercise price for 361,011 warrant shares

Exercise price tranche 2

$18.64

Exercise price for 133,248 warrant shares

Max cash from warrant

$6,877,246.59

Gross proceeds if all registered warrant shares exercised for cash

Underwritten offering size

4,691,358 shares at $20.25

Oct 31, 2025 prospectus supplement

Registered direct shares

740,740 shares at $20.25

Concurrent registered direct sale

Current share price

$29.99

Pre-news trading level vs 52-week range $14–$30.68

Historical Context

5 past events · Latest: Feb 18

5 events

1. Feb 18

   Managerial transactions

   24h Move

   -0.6%

   Disclosure of earnout share vesting and removal of related restrictions for four managers.

2. Feb 17

   Executive appointment

   24h Move

   +1.0%

   Appointment of Chief Legal Officer ahead of key Phase 3 readouts and programs.

3. Jan 08

   Pipeline showcase

   24h Move

   +5.0%

   Showcase of late-stage ophthalmology pipeline and upcoming pivotal milestones at JPM conference.

4. Jan 06

   Regulatory milestone

   24h Move

   +5.8%

   FDA Breakthrough Therapy Designation for Privosegtor based on positive Phase 2 ACUITY data.

5. Jan 05

   RSU vesting notice

   24h Move

   +5.8%

   Administrative notification of RSU vesting and settlement for a director with no financial details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

RSUs

1 terms

RSUs financial

"relates to the vesting and settlement of RSUs previously granted to a director"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Arshad Khanani - 25 February 2026 RSU vest

FAQ

What did Oculis announce about the RSU vesting for director Arshad Khanani (OCS) on February 27, 2026?

Oculis announced the vesting and settlement of RSUs for director Arshad Khanani on 25 February 2026. According to Oculis, the notification documents the managers' transaction and confirms the prior RSU grant vested and settled as described.

Does the Oculis (OCS) notification on February 27, 2026) indicate any cash payment or stock issuance amount?

The notification reports vesting and settlement of RSUs but does not state cash amounts or share counts. According to Oculis, the attached notice simply documents the manager transaction without providing financial quantities.

When did the RSUs for Oculis director Arshad Khanani actually vest according to the Oculis (OCS) notice?

The RSUs for director Arshad Khanani vested on 25 February 2026, per the notification. According to Oculis, the published notice dated 27 February 2026 references that vest date for the settled RSUs.

Is the Oculis (OCS) managers' transaction notification on February 27, 2026 a regulatory filing or internal disclosure?

The notification is a managers' transaction disclosure documenting RSU vesting by a director. According to Oculis, it serves as a regulatory-style notification of the director's vested and settled equity award.

What should investors know about the impact of the RSU vesting notice for Oculis (OCS) dated February 27, 2026?

The notice records a director's RSU vesting and settlement but provides no financial metrics or guidance. According to Oculis, the disclosure is informational and does not specify amounts that would indicate material impact.